Robert W. Baird Issues Positive Forecast for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price target hoisted by research analysts at Robert W. Baird from $230.00 to $249.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price points to a potential upside of 28.66% from the stock’s previous close.

Several other analysts also recently issued reports on IQV. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada assumed coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $222.00.

IQVIA Trading Up 0.1%

IQV stock opened at $193.53 on Wednesday. IQVIA has a twelve month low of $154.50 and a twelve month high of $247.04. The stock has a market capitalization of $32.30 billion, a price-to-earnings ratio of 23.98, a price-to-earnings-growth ratio of 1.66 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm’s fifty day simple moving average is $175.19 and its two-hundred day simple moving average is $189.44.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts anticipate that IQVIA will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Institutional Trading of IQVIA

A number of large investors have recently modified their holdings of the company. Ameliora Wealth Management Ltd. bought a new position in IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the 4th quarter worth $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA during the 4th quarter worth $27,000. CrossGen Wealth LLC purchased a new position in shares of IQVIA during the fourth quarter valued at $28,000. Finally, Activest Wealth Management increased its stake in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.